Aldeyra Therapeutics, Inc to Post Q4 2024 Earnings of $1.42 Per Share, Leerink Partnrs Forecasts (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Investment analysts at Leerink Partnrs lifted their Q4 2024 earnings per share estimates for shares of Aldeyra Therapeutics in a report issued on Tuesday, May 21st. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings of $1.42 per share for the quarter, up from their prior estimate of $1.38. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.15) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ FY2027 earnings at $1.45 EPS and FY2028 earnings at $2.50 EPS.

ALDX has been the subject of a number of other reports. Oppenheimer reiterated an “outperform” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Monday, May 6th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Monday, May 6th. Finally, StockNews.com downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday.

Aldeyra Therapeutics Trading Down 1.8 %

ALDX stock opened at $3.87 on Thursday. The firm has a 50 day moving average of $3.79 and a 200-day moving average of $3.39. Aldeyra Therapeutics has a 12-month low of $1.42 and a 12-month high of $11.97. The company has a market cap of $229.93 million, a price-to-earnings ratio of -7.59 and a beta of 1.45.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.13.

Insider Buying and Selling at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, CEO Todd C. Brady sold 97,914 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.27, for a total value of $320,178.78. Following the completion of the transaction, the chief executive officer now directly owns 1,556,622 shares in the company, valued at approximately $5,090,153.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Todd C. Brady sold 97,914 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.27, for a total transaction of $320,178.78. Following the completion of the sale, the chief executive officer now directly owns 1,556,622 shares of the company’s stock, valued at approximately $5,090,153.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bruce Greenberg sold 13,201 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.41, for a total transaction of $45,015.41. Following the sale, the insider now directly owns 120,699 shares of the company’s stock, valued at $411,583.59. The disclosure for this sale can be found here. In the last three months, insiders acquired 355,933 shares of company stock worth $1,473,245. Insiders own 8.50% of the company’s stock.

Institutional Trading of Aldeyra Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Prime Capital Investment Advisors LLC purchased a new stake in Aldeyra Therapeutics during the 4th quarter worth $35,000. SG Americas Securities LLC acquired a new position in Aldeyra Therapeutics in the 4th quarter worth $39,000. NorthRock Partners LLC acquired a new position in Aldeyra Therapeutics in the 4th quarter worth $42,000. Kingswood Wealth Advisors LLC acquired a new position in Aldeyra Therapeutics in the 1st quarter worth $49,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Aldeyra Therapeutics by 1,064.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 22,167 shares of the biotechnology company’s stock worth $78,000 after buying an additional 20,264 shares in the last quarter. 59.71% of the stock is owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.